表紙
市場調査レポート

MediPoint:下肢用末梢血管ステント - 南米市場の分析と予測

MediPoint: Peripheral Vascular Stents for the Lower Extremity - South America Analysis and Market Forecasts

発行 GlobalData 商品コード 270726
出版日 ページ情報 英文 313 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
MediPoint:下肢用末梢血管ステント - 南米市場の分析と予測 MediPoint: Peripheral Vascular Stents for the Lower Extremity - South America Analysis and Market Forecasts
出版日: 2013年04月30日 ページ情報: 英文 313 Pages
概要

当レポートでは、南米諸国(ブラジルなど)における下肢用末梢血管ステントの市場について分析し、関連疾患(末梢動脈疾患など)の概要、市場の構造と動向(過去3年間の実績値と今後7年間の予測値)、市場機会とアンメットニーズ、主な上市済み/開発中の製品の概要、全体的な産業構造・動向、市場の主な促進要因と課題、各国市場の概況・将来展望などを調査して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 末梢動脈疾患

  • 概要
  • 生体構造・生理機能
    • 下肢の末梢動脈
  • 病態
  • 臨床所見
    • 末梢動脈疾患の兆候
    • リスク要因
    • 疾患の分類
    • 診断
  • 臨床転帰
    • 治療パラダイム
    • 治療ガイドライン
    • 治療の様式
    • 末梢動脈疾患の血管管理
  • 疫学:末梢動脈疾患
  • 経済的影響:南米(ブラジル)の場合

第4章 競争環境

  • 概要
    • 末梢血管ステント市場
  • 製品
    • ベアメタルステント
    • 薬剤溶出性ステント
    • カバード(被覆)ステント
    • 生体吸収性ステント

第5章 アンメットニーズ

  • 特異性障害に関するより良い臨床転機の必要性
  • 医薬療法の改善の必要性
  • 運動療法の比較研究
  • 下肢バイパス手術の複雑性への対処
  • バルーン血管形成術の失敗メカニズムの除去
  • より良い大腿膝窩動脈の再生の必要性
  • 膝窩動脈下動脈の治療の難しさ
  • 臨床データの欠如
  • 低プロファイル機器の設計の限界
  • 末梢血管ステントに関する課題への対処

第6章 パイプライン製品

  • 概要
  • 開発段階別のパイプライン
  • パイプライン製品のプロファイル(全18製品)

第7章 治験分析

  • 概要
  • 注目すべき治験(全10件)

第8章 競争力評価

  • 治療法の傾向
    • 末梢血管侵襲式治療の普及促進要因
    • 南米の場合
  • 市場アクセス:南米の場合
  • 医療費償還の傾向:南米の場合
  • 規制上の課題/リコール
  • 企業合併・買収(M&A)事例(計9件)

第9章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル(全33社)

第10章 市場の促進要因・機会・障壁

  • 市場促進要因
    • 疾患の有病率の上昇
    • 血管の長期的な開存性
    • 再狭窄リスクの軽減
    • 自己拡張型ニチロールステント
    • 手足の切断
    • コストの考察
    • 長期的データの入手可能性
    • 「ステント・イン・ステント」処置の回避
    • 二重抗血小板療法の必要性の軽減
    • ステントの正確な設置
    • 米国での血管ステント製品の発売予定
  • 市場機会
    • 末梢血管ステント市場
    • 大腿膝窩動脈・膝窩動脈下動脈の治療に関する課題
    • 生体分解性・生体吸収性ステント
    • 高リスク患者を対象とした製品
    • 日本市場での血管ステント製品の発売
    • 新興国市場
  • 市場の障壁
    • 導入の遅さ
    • 販売価格の高さ
    • 医療費償還制度の欠如
    • 代替的製品

第11章 各国市場の見通しと予測

  • ブラジル
    • 概要
    • 市場分析

第12章 付録

図表一覧

目次
Product Code: GDME1031CFR

Summary

Endovascular therapies such as stenting have been widely adopted to treat peripheral artery disease (PAD) in the lower extremity. Peripheral vascular stents including bare metal, drug-eluting, covered and bioabsorbable stents are associated with improved clinical outcomes compared to balloon angioplasty alone. The global peripheral vascular stent (PVS) market is steadily growing in the 10 countries covered in the report, including the US, France, Germany, Italy, Spain, UK, Japan, Brazil, China and India. Through GlobalData's analysis, it is evident that currently the peripheral vascular stent market for the lower extremity is saturated with bare metal stents, followed by covered stents. However, as clinical data and appropriate reimbursement and costs are established, adoption of innovative stent technologies such as drug-eluting stents and bioabsorbable stents will increase in the future.

The peripheral vascular stent market is a large and dynamic one that allows stent manufacturers to develop different types of vascular stent platforms for different types of arteries in the lower extremity. As PAD presents enormous global public health and socioeconomic issues, it is pertinent to find effective treatment modalities that ensure long-term quality results for patients. This report looks at the current peripheral vascular stent market for the lower extremity in South America (Brazil), and evaluates the adoption and opportunities for this technology in this market.

Scope

  • An overview of PAD, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized South America PVS market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
  • Investigation of current and future market competition for PVS
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the PVS sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as cardiologists

Reasons to buy

  • Understand the trends shaping and driving South America PVS Market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the US PVS Market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in South America PVS market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Peripheral Artery Disease

  • 3.1. Overview
  • 3.2. Anatomy and Physiology
    • 3.2.1. Peripheral Arteries of the Lower Extremity
  • 3.3. Pathophysiology
  • 3.4. Clinical Presentation
    • 3.4.1. Symptoms of Peripheral Artery Disease
    • 3.4.2. Risk Factors
    • 3.4.3. Disease Classification
    • 3.4.4. Diagnosis
  • 3.5. Clinical Outcomes
    • 3.5.1. Treatment Paradigm
    • 3.5.2. Treatment Guidelines
    • 3.5.3. Treatment Modalities
    • 3.5.4. Endovascular Management of PAD
  • 3.6. Epidemiology
    • 3.6.1. Peripheral Artery Disease
  • 3.7. Economic Impact
    • 3.7.1. South America (Brazil)

4. Competitive Assessment

  • 4.1. Overview
    • 4.1.1. Peripheral Vascular Stent Market
  • 4.2. Products
    • 4.2.1. Bare Metal Stents
    • 4.2.2. Drug-Eluting Stents
    • 4.2.3. Covered Stents
    • 4.2.4. Bioabsorbable Stents

5. Unmet Needs

  • 5.1. Need for Better Clinical Outcomes in Specific Lesions
    • 5.1.1. Chronic Total Occlusions
    • 5.1.2. Long Lesions
    • 5.1.3. Heavily-Calcified and Uncrossable Lesions
    • 5.1.4. Bifurcation Lesions
  • 5.2. Need to Improve Medical Therapy
  • 5.3. Comparative Studies on Exercise Therapy
  • 5.4. Addressing Complications of Lower-Extremity Bypass Surgery
  • 5.5. Eliminating Mechanisms of Failure with Balloon Angioplasty
  • 5.6. Need for Better Revascularization of the Femoropopliteal Artery
  • 5.7. Difficulty in Treating the Infrapopliteal Artery
  • 5.8. Lack of Clinical Data
  • 5.9. Limited Designs of Low-Profile Devices
  • 5.10. Addressing Challenges of Peripheral Stenting
    • 5.10.1. Risk of Post-Procedural Complications
    • 5.10.2. In-Stent Restenosis
    • 5.10.3. Stent Fracture
    • 5.10.4. Long-Term Vessel Patency
    • 5.10.5. Stent Material
    • 5.10.6. Stent Deployment and Deliverability
    • 5.10.7. Dual Anti-Platelet Therapy
    • 5.10.8. Imaging

6. Pipeline Products

  • 6.1. Overview
  • 6.2. Pipeline by Phase of Development
  • 6.3. Pipeline Product Profiles - Peripheral Artery Disease
    • 6.3.1. Citation Stent
    • 6.3.2. MR-Enhanced Stents
    • 6.3.3. ArtiStent
    • 6.3.4. Hybrid Dynamic Stent
    • 6.3.5. Nipro Corporation Peripheral Stent
    • 6.3.6. Yukon
    • 6.3.7. iCAST
    • 6.3.8. Peritoneal-Lined Stents
    • 6.3.9. LifeJacket Stent Graft
    • 6.3.10. Esprit Bioabsorbable Vascular Scaffold (BVS)
    • 6.3.11. Magic Explorer Stent
    • 6.3.12. Stanza
    • 6.3.13. 3D Biotek Bioresorbable Stent
    • 6.3.14. Archer Stent
    • 6.3.15. ART Stent
    • 6.3.16. Amaranth Bioabsorbable Scaffold
    • 6.3.17. TephaFLEX Absorbable Peripheral Stent
    • 6.3.18. Zorion Medical Stent
    • 6.3.19. Summary

7. Clinical Trial Analysis

  • 7.1. Overview
  • 7.2. Trials to Watch
    • 7.2.1. Abbott Vascular
    • 7.2.2. Atrium Medical Corporation
    • 7.2.3. Biotronik
    • 7.2.4. 480 Biomedical
    • 7.2.5. Cook Medical
    • 7.2.6. Covidien
    • 7.2.7. Flexible Stenting Solutions
    • 7.2.8. IDEV Technologies
    • 7.2.9. Medtronic
    • 7.2.10. Terumo Medical Corporation

8. Industry Overview

  • 8.1. Procedure Trends
    • 8.1.1. Factors Contributing to Rise of Peripheral Interventions
    • 8.1.2. South America
  • 8.2. Market Access
    • 8.2.1. South America
  • 8.3. Reimbursement Trends
    • 8.3.1. South America
  • 8.4. Regulatory Issues/Recalls
    • 8.4.1. Regulatory Issues
    • 8.4.2. Recalls
  • 8.5. Mergers and Acquisitions
    • 8.5.1. Abbott Laboratories
    • 8.5.2. Atrium Medical Corporation
    • 8.5.3. Boston Scientific Corporation
    • 8.5.4. Cordis Corporation (Johnson & Johnson)
    • 8.5.5. Covidien
    • 8.5.6. CR Bard
    • 8.5.7. Medtronic
    • 8.5.8. Nexeon Stent
    • 8.5.9. Terumo Corporation

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Abbott Vascular
    • 9.3.2. Amaranth Medical
    • 9.3.3. Arterial Remodeling Technologies
    • 9.3.4. Atrium Medical Corporation
    • 9.3.5. Bard Peripheral Vascular (C.R. Bard)
    • 9.3.6. Biotronik
    • 9.3.7. Boston Scientific Corporation
    • 9.3.8. 3D Biotek
    • 9.3.9. 480 Biomedical
    • 9.3.10. Cook Medical
    • 9.3.11. Cordis Corporation (Johnson & Johnson)
    • 9.3.12. CorInnova
    • 9.3.13. Covidien
    • 9.3.14. Cytograft Tissue Engineering
    • 9.3.15. Flexible Stenting Solutions
    • 9.3.16. IDEV Technologies
    • 9.3.17. Kyoto Medical Planning
    • 9.3.18. Medtronic
    • 9.3.19. Nexeon Stent
    • 9.3.20. Nipro Corporation
    • 9.3.21. NovoStent Corporation
    • 9.3.22. OptiMed
    • 9.3.23. PeriTec Biosciences
    • 9.3.24. Synergy Flow
    • 9.3.25. Tepha
    • 9.3.26. Terumo Corporation
    • 9.3.27. TissueGen
    • 9.3.28. Translumina
    • 9.3.29. Vascular Concepts
    • 9.3.30. Veryan Medical
    • 9.3.31. VueKlar Cardiovascular
    • 9.3.32. W.L. Gore & Associates
    • 9.3.33. Zorion Medical

10. Market Drivers, Opportunities and Barriers

  • 10.1. Market Drivers
    • 10.1.1. Rising Prevalence of Disease
    • 10.1.2. Long-Term Vessel Patency
    • 10.1.3. Reducing the Risk of Restenosis
    • 10.1.4. Low-Profile Stent System
    • 10.1.5. Self-Expanding Nitinol Stents
    • 10.1.6. Limb Amputation
    • 10.1.7. Cost Considerations
    • 10.1.8. Availability of Long-Term Data
    • 10.1.9. Avoiding Stent-in-Stent Procedures
    • 10.1.10. Reducing the Need for Dual Anti-Platelet Therapy
    • 10.1.11. Accurate Stent Placement
    • 10.1.12. Expected Launch of Vascular Stent Products in the US
  • 10.2. Opportunities
    • 10.2.1. Peripheral Stent Market
    • 10.2.2. Challenges in Treating the Femoropopliteal and Infrapopliteal Arteries
    • 10.2.3. Biodegradable and Bioabsorbable Stents
    • 10.2.4. Target High-Risk Patients
    • 10.2.5. Launch Vascular Stents in the Japanese Market
    • 10.2.6. Emerging Markets
  • 10.3. Market Barriers
    • 10.3.1. Slow Adoption
    • 10.3.2. High Selling Prices
    • 10.3.3. Lack of Reimbursement
    • 10.3.4. Substitutes

11. Country Outlooks and Forecasts

  • 11.1. Brazil
    • 11.1.1. Overview
    • 11.1.2. Market Analysis

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Report Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
    • 12.3.4. Forecasting Methodology
  • 12.4. Physicians and Specialists Included in this Study
  • 12.5. Physician Survey
  • 12.6. About the Authors
    • 12.6.1. Analysts
    • 12.6.2. Global Head of Healthcare
  • 12.7. About MediPoint
  • 12.8. About GlobalData
  • 12.9. Contact Us
  • 12.10. Disclaimer

List of Tables

  • Table 1: Classification Systems for Determining the Severity of PAD Symptoms
  • Table 2: Risk Factors Associated with Peripheral Artery Disease
  • Table 3: Types of Atherosclerotic Lesions
  • Table 4: TASC II Classification of Iliac Artery Lesions
  • Table 5: TASC II Classification of Femoropopliteal Artery Lesions
  • Table 6: TASC II Classification of Infrapopliteal Artery Lesions
  • Table 7: Complications of Peripheral Artery Bypass Surgery
  • Table 8: Drugs Incorporated Into Drug-Eluting Stents
  • Table 9: Types of Lesions Treated Using Atherectomy
  • Table 10: Prevalence of PAD in Population Age ≥65 Years in Brazil, millions, 2010-2019
  • Table 11: Direct and Indirect Healthcare Costs
  • Table 12:Peripheral Vascular Stent Market ($m) for Each Type of Artery in the Lower Extremity in Brazil, 2012
  • Table 13: Marketed Bare Metal Stent Products
  • Table 14: Absolute Stent Family Product Portfolio
  • Table 15: Absolute Stent SWOT Analysis, 2013
  • Table 16: Astron Stent Product Portfolio
  • Table 17: Astron Stent SWOT Analysis, 2013
  • Table 18: BioMimics 3D Stent Product Portfolio
  • Table 19: BioMimics 3D Stent SWOT Analysis, 2013
  • Table 20: Complete Stent SE Product Portfolio
  • Table 21: Complete SE Stent SWOT Analysis, 2013
  • Table 22: E-Luminexx Stent Product Portfolio
  • Table 23: E-Luminexx Stent SWOT Analysis, 2013
  • Table 24: Epic Stent Product Portfolio
  • Table 25: Epic Stent SWOT Analysis, 2013
  • Table 26: FlexStent Iliac Stent System Product Portfolio
  • Table 27: FlexStent Iliac Stent System SWOT Analysis, 2013
  • Table 28: LifeStent Vascular Stent System Product Portfolio
  • Table 29: LifeStent Vascular Stent System SWOT Analysis, 2013
  • Table 30: Maris Deep Stent Product Portfolio
  • Table 31: Maris Deep Stent SWOT Analysis, 2013
  • Table 32: Maris Plus Stent Product Portfolio
  • Table 33: Maris Plus Stent SWOT Analysis, 2013
  • Table 34: Misago Stent Product Portfolio
  • Table 35: Misago Stent SWOT Analysis, 2013
  • Table 36: NovoStent Samba Stent System Product Portfolio
  • Table 37: NovoStent Samba Stent System SWOT Analysis, 2013
  • Table 38: Protege Family of Stents Product Portfolio
  • Table 39: Protege Family of Stents SWOT Analysis, 2013
  • Table 40: Pulsar 18 Stent Product Portfolio
  • Table 41: Pulsar 18 Stent SWOT Analysis, 2013
  • Table 42: SMART Stent Product Portfolio
  • Table 43: SMART Stent SWOT Analysis, 2013
  • Table 44: Sinus Stent Family Product Portfolio
  • Table 45: Sinus Stent Family SWOT Analysis, 2013
  • Table 46: Supera Veritas Stent Product Portfolio
  • Table 47: Supera Veritas Stent SWOT Analysis, 2013
  • Table 48: Wallstent Product Portfolio
  • Table 49: Wallstent SWOT Analysis, 2013
  • Table 50: Xpert Stent Product Portfolio
  • Table 51: Xpert Stent SWOT Analysis, 2013
  • Table 52: Zilver Stent Product Portfolio
  • Table 53: Zilver Stent SWOT Analysis, 2013
  • Table 54: Assurant Cobalt Stent Product Portfolio
  • Table 55: Assurant Cobalt Stent SWOT Analysis, 2013
  • Table 56: Chromis Deep Stent Product Portfolio
  • Table 57: Chromis Deep Stent SWOT Analysis, 2013
  • Table 58: Dynamic Stent Product Portfolio
  • Table 59: Dynamic Stent SWOT Analysis, 2013
  • Table 60: Express LD Product Portfolio
  • Table 61: Express LD SWOT Analysis, 2013
  • Table 62: IntraStent LD Stent Product Portfolio
  • Table 63: IntraStent LD Stent SWOT Analysis, 2013
  • Table 64: Omnilink Elite Stent Product Portfolio
  • Table 65: Omnilink Elite Stent SWOT Analysis, 2013
  • Table 66: ParaMount Mini GPS Product Portfolio
  • Table 67: ParaMount Mini GPS SWOT Analysis, 2013
  • Table 68: ProStar Stent Product Portfolio
  • Table 69: ProStar Stent SWOT Analysis, 2013
  • Table 70: Scuba Stent Product Portfolio
  • Table 71: Scuba Stent SWOT Analysis, 2013
  • Table 72: Visi-Pro Stent Product Portfolio
  • Table 73: Visi-Pro Stent SWOT Analysis, 2013
  • Table 74: Marketed Drug-Eluting Stent Products
  • Table 75: Xience Prime BTK Stent Product Portfolio
  • Table 76: Xience Prime BTK Stent SWOT Analysis, 2013
  • Table 77: Zilver PTX Stent Product Portfolio
  • Table 78: Zilver PTX Stent SWOT Analysis, 2013
  • Table 79: Marketed Covered Stent Products
  • Table 80: Gore Viabahn Stent Product Portfolio
  • Table 81: Gore Viabahn Stent SWOT Analysis, 2013
  • Table 82: Gore Tigris Stent Product Portfolio
  • Table 83: Gore Tigris Stent SWOT Analysis, 2013
  • Table 84: V12 Covered Stents Product Portfolio
  • Table 85: V12 Covered Stents SWOT Analysis, 2013
  • Table 86: Remedy Stent Product Portfolio
  • Table 87: Remedy Stent SWOT Analysis, 2012
  • Table 88: Peripheral Vascular Stent Product Pipeline
  • Table 89: Citation Stent SWOT Analysis, 2013
  • Table 90: MR-Enhanced Stents SWOT Analysis, 2013
  • Table 91: Yukon Stent SWOT Analysis, 2013
  • Table 92: iCAST Stent SWOT Analysis, 2013
  • Table 93: Peritoneal-Lined Stents SWOT Analysis, 2013
  • Table 94: Esprit BVS SWOT Analysis, 2013
  • Table 95: Magic Explorer Stent SWOT Analysis, 2013
  • Table 96: Stanza Stent SWOT Analysis, 2013
  • Table 97: 3D Biotek Bioresorbable Stent SWOT Analysis, 2013
  • Table 98: Archer Stent SWOT Analysis, 2013
  • Table 99: Abbott Vascular Company Profile
  • Table 100: Abbott Vascular, Marketed and Pipeline Vascular Stent Products
  • Table 101: Abbott Vascular SWOT Analysis, 2013
  • Table 102: Amaranth Medical Company Profile
  • Table 103: Amaranth Medical, Pipeline Vascular Stent Product
  • Table 104: Amaranth Medical SWOT Analysis, 2013
  • Table 105: Arterial Remodeling Technologies Company Profile
  • Table 106: Arterial Remodeling Technologies, Pipeline Vascular Stent Product
  • Table 107: Arterial Remodeling Technologies SWOT Analysis, 2013
  • Table 108: Atrium Medical Corporation Company Profile
  • Table 109: Atrium Medical Corporation, Marketed and Pipeline Vascular Stent Products
  • Table 110: Atrium Medical Corporation SWOT Analysis, 2013
  • Table 111: Bard Peripheral Vascular (C.R. Bard) Company Profile
  • Table 112: Bard Peripheral Vascular (C.R. Bard), Marketed Vascular Stent Products
  • Table 113: Bard Peripheral Vascular (C.R. Bard) SWOT Analysis, 2013
  • Table 114: Biotronik Company Profile
  • Table 115: Biotronik, Marketed and Pipeline Vascular Stent Products
  • Table 116: Biotronik SWOT Analysis, 2013
  • Table 117: Boston Scientific Corporation Company Profile
  • Table 118: Boston Scientific Corporation, Marketed Vascular Stent Products
  • Table 119: Boston Scientific Corporation SWOT Analysis, 2013
  • Table 120: Company Profile - 3D Biotek
  • Table 121: 3D Biotek, Pipeline Vascular Stent Product
  • Table 122: 3D Biotek SWOT Analysis, 2013
  • Table 123: 480 Biomedical Company Profile
  • Table 124: 480 Biomedical, Pipeline Vascular Stent Product
  • Table 125: 480 Biomedical SWOT Analysis, 2013
  • Table 126: Cook Medical Company Profile
  • Table 127: Cook Medical, Marketed Vascular Stent Products
  • Table 128: Cook Medical SWOT Analysis, 2013
  • Table 129: Cordis Corporation Company Profile
  • Table 130: Cordis Corporation, Marketed Vascular Stent Product
  • Table 131: Cordis Corporation SWOT Analysis, 2013
  • Table 132: CorInnova Company Profile
  • Table 133: CorInnova, Pipeline Vascular Stent Product
  • Table 134: CorInnova SWOT Analysis, 2013
  • Table 135: Covidien Company Profile
  • Table 136: Covidien, Marketed Vascular Stent Products
  • Table 137: Covidien SWOT Analysis, 2013
  • Table 138: Company Profile - Cytograft Tissue Engineering
  • Table 139: Cytograft Tissue Engineering, Pipeline Vascular Stent Product
  • Table 140: Cytograft Tissue Engineering SWOT Analysis, 2013
  • Table 141: Flexible Stenting Solutions Company Profile
  • Table 142: Flexible Stenting Solutions, Marketed Vascular Stent Product
  • Table 143: Flexible Stenting Solutions SWOT Analysis, 2013
  • Table 144: IDEV Technologies Company Profile
  • Table 145: IDEV Technologies, Marketed Vascular Stent Product
  • Table 146: IDEV Technologies SWOT Analysis, 2013
  • Table 147: Kyoto Medical Planning Company Profile
  • Table 148: Kyoto Medical Planning, Marketed Vascular Stent Product
  • Table 149: Kyoto Medical Planning SWOT Analysis, 2013
  • Table 150: Medtronic Company Profile
  • Table 151: Medtronic's Marketed Vascular Stent Products
  • Table 152: Medtronic SWOT Analysis, 2013
  • Table 153: Nexeon Stent Company Profile
  • Table 154: Nexeon Stent, Pipeline Vascular Stent Product
  • Table 155: Nexeon Stent SWOT Analysis, 2013
  • Table 156: Nipro Corporation Company Profile
  • Table 157: Nipro Corporation, Pipeline Vascular Stent Product
  • Table 158: Nipro Corporation SWOT Analysis, 2013
  • Table 159: NovoStent Corporation Company Profile
  • Table 160: NovoStent Corporation, Marketed Vascular Stent Product
  • Table 161: NovoStent Corporation SWOT Analysis, 2013
  • Table 162: OptiMed Company Profile
  • Table 163: OptiMed, Marketed Vascular Stent Products
  • Table 164: OptiMed SWOT Analysis, 2013
  • Table 165: Company Profile - PeriTec Biosciences
  • Table 166: PeriTec Biosciences, Pipeline Vascular Stent Product
  • Table 167: PeriTec Biosciences SWOT Analysis, 2013
  • Table 168: Synergy Flow Company Profile
  • Table 169: Synergy Flow, Pipeline Vascular Stent Product
  • Table 170: Synergy Flow SWOT Analysis, 2013
  • Table 171: Tepha Company Profile
  • Table 172: Tepha Medical Device, Pipeline Vascular Stent Product
  • Table 173: Tepha SWOT Analysis, 2013
  • Table 174: Terumo Corporation Company Profile
  • Table 175: Terumo Corporation, Marketed Vascular Stent Products
  • Table 176: Terumo Corporation SWOT Analysis, 2013
  • Table 177: TissueGen Company Profile
  • Table 178: TissueGen, Pipeline Vascular Stent Product
  • Table 179: TissueGen SWOT Analysis, 2013
  • Table 180: Translumina Company Profile
  • Table 181: Translumina, Pipeline Vascular Stent Product
  • Table 182: Translumina SWOT Analysis, 2013
  • Table 183: Vascular Concepts Company Profile
  • Table 184: Vascular Concept, Marketed Vascular Stent Product
  • Table 185: Vascular Concepts SWOT Analysis, 2013
  • Table 186: Company Profile - Veryan Medical
  • Table 187: Veryan Medical, Marketed Vascular Stent Product
  • Table 188: Veryan Medical SWOT Analysis, 2013
  • Table 189: VueKlar Cardiovascular Company Profile
  • Table 190: VueKlar Cardiovascular, Pipeline Vascular Stent Product
  • Table 191: VueKlar Cardiovascular SWOT Analysis, 2013
  • Table 192: W.L. Gore & Associates Company Profile
  • Table 193: W.L. Gore & Associates, Marketed Vascular Stent Products
  • Table 194: W.L. Gore & Associates SWOT Analysis, 2013
  • Table 195: Zorion Medical Company Profile
  • Table 196: Zorion Medical, Pipeline Vascular Stent Product
  • Table 197: Zorion Medical SWOT Analysis, 2013
  • Table 198: Peripheral Vascular Stent Sales ($m) Forecast for Brazil, 2010-2019
  • Table 199: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Peripheral Arteries of the Lower Extremity
  • Figure 2: Pathophysiology of Peripheral Artery Disease
  • Figure 3: Treatment Modalities - Peripheral Artery Disease
  • Figure 4: Percent of Patients with Peripheral Artery Disease Who Receive Each Therapy Option Only, South America, 2012 (n=5)
  • Figure 5: Treatment of PAD, South America*, 2012 and 2018 (n=5)
  • Figure 6: Types of Stents Used to Treat Peripheral Artery Disease
  • Figure 7: Bare Metal Stent For Treating Peripheral Artery Disease
  • Figure 8: Drug-Eluting Stent for Treating Peripheral Artery Disease
  • Figure 9: Covered Stents For Treating Peripheral Artery Disease
  • Figure 10: Types of Atherectomy
  • Figure 11: Prevalence of PAD in Population Age ≥65 Years in Brazil, millions, 2010-2019
  • Figure 12: Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity in Brazil ($), 2012
  • Figure 13: Peripheral Vascular Stent Market ($m) for Each Type of Artery in Brazil, 2012
  • Figure 14: Remedy Stent for Treating Peripheral Artery Disease
  • Figure 15: Pipeline Peripheral Vascular Stent Products, 2013
  • Figure 16: Peripheral Vascular Stent Pipeline by Stage of Clinical Development, 2013
  • Figure 17: Population (≥ 65 years) with PAD Receiving Interventional Procedures for the Peripheral Arteries in the Lower Extremity, Brazil, 2010-2019
  • Figure 18: Population (≥ 65 years) with PAD Receiving Stenting for the Peripheral Arteries in the Lower Extremity, Brazil, 2010-2019
  • Figure 19: Peripheral Vascular Stent Market for Treating Peripheral Artery Disease in the Lower Extremity, Company Share (%), 2012
  • Figure 20: Peripheral Vascular Stent Market for Each Type of Artery, Company Share (%), 2012
  • Figure 21: Kyoto Medical Planning, Sales Volume ($m), May 2002-May 2012
  • Figure 22: Likelihood of Physician Adoption of Each Type of Vascular Stent in the Future for Treating Peripheral Artery Disease in the Lower Extremity, Global (n=50)
  • Figure 23: Importance of Each Attribute in Adopting Vascular Stents to Treat Peripheral Artery Disease in the Lower Extremity, Global, (n=50)
  • Figure 24: Brazilian Peripheral Vascular Stent Market ($m) for the Lower Extremity, 2010-2019
Back to Top